Ken Griffin Inozyme Pharma, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$4.31 - $6.0 $13,360 - $18,600	3,100 Added 114.81%	5,800 $30,000
Q2 2024 Aug 14, 2024	SELL	$4.33 - $7.31 $13,856 - $23,392	-3,200 Reduced 54.24%	2,700 $12,000
Q1 2024 May 15, 2024	SELL	$4.14 - $7.66 $20,286 - $37,534	-4,900 Reduced 45.37%	5,900 $45,000
Q4 2023 Feb 14, 2024	BUY	$2.71 - $4.5 $2,710 - $4,500	1,000 Added 10.2%	10,800 $46,000
Q3 2023 Nov 14, 2023	SELL	$4.09 - $7.0 $46,217 - $79,100	-11,300 Reduced 53.55%	9,800 $41,000
Q2 2023 Aug 14, 2023	SELL	$4.93 - $6.74 $8,381 - $11,458	-1,700 Reduced 7.46%	21,100 $117,000
Q1 2023 May 15, 2023	BUY	$1.3 - $5.73 $29,640 - $130,644	22,800 New	22,800 $130,000

53M

3.7K

5.8K

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $110M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.